Results 51 to 60 of about 43,790 (236)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Retrospective evaluation of patients with elevated digoxin levels at an emergency department

Turkish Journal of Emergency Medicine, 2016
Objectives: We investigated the demographic characteristics, clinical and laboratory findings, treatment strategies and clinical outcomes of patients presenting at emergency department (ED) with digoxin levels at or above 1.2 ng/ml. Materials and methods:
Gulsum Limon, Gurkan Ersoy, Nese Colak Oray, Basak Bayram, Onder Limon   +4 more
doaj   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, EarlyView.
What's New? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Preparation of Nanoparticles of Digoxin Solid Lipid

Chemical Engineering Transactions, 2017
In order to prove the role of solid lipid nanoparticles in oral absorption and bioavailability, the biodegradable monoglyceride with low toxicity and good biocompatibility is used as lipid materials to prepare nanoparticles of digoxin solid lipid and ...
Ping Luo, Yangwu Liu
doaj   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

The Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol, Jason H. Williams, Haihong Shi, Derek Z. Yang, Justin Hoffman, Diane D. Wang   +5 more
wiley   +1 more source

Cardiac resynchronization therapy and pulmonary artery banding in advanced heart failure infants with left ventricular dilated cardiomyopathy and left bundle branch block

Pediatric Investigation, EarlyView.
The combination of cardiac resynchronization therapy and pulmonary artery banding was associated with substantial improvement in advanced heart failure infants with left ventricular dilated cardiomyopathy and left bundle branch block. Most patients exhibited marked improvement in clinical status and ventricular function, along with a reduction in QRS ...
Min Zeng, Fan Yang, Quanlin Li, Kai Ma, Zheng Dou, Kunjing Pang, Xinjie Lin, Shoujun Li, Xu Wang   +8 more
wiley   +1 more source

Digoxin revisited [PDF]

QJM, 1998
F L, Li-Saw-Hee, G Y, Lip
openaire   +4 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells

Small Methods, EarlyView.
Cardenolide‐functionalized extracellular vesicles enable targeted delivery of the chemotherapeutic doxorubicin to A549 lung cancer cells by binding Na+/K+‐ATPase, which is overexpressed in these cells. Surface‐modified, drug‐loaded EVs exhibit enhanced cytotoxicity compared to unmodified EVs and free drug, suggesting this system may lower the effective
Maja Dorfner, Anika Mifka, Rodrigo Maia de Pádua, Izabella Thaís da Silva, Iara Zanella Guterres, Lorenzo Sana, Gregor Fuhrmann, Jennifer Munkert   +7 more
wiley   +1 more source